The Q1 results confirm the COVID-19 revenue decline trajectory is on track with guidance, but the widening net loss and CEO succession uncertainty create near-term overhang. The oncology pipeline catalysts (pumitamig Phase 2 data at ASCO, gotistobart Phase 3 interim, trastuzumab pamirtecan BLA filing) represent the primary value drivers for 2026. The $1.0B buyback provides a floor but does not offset fundamental deterioration. Monitor the May 29 ASCO data readout for pumitamig as a key inflection point.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 5 $95.50entry
- T+1 · 7mo ago −0.25%α −1.64% · $95.26
- T+5 · 6mo ago −1.93%α −3.91% · $93.66
- T+20 · 6mo ago −6.66%α −11.61% · $89.14
- T+60 · 4mo ago −2.77%α −5.51% · $92.85
Price Chart
How similar events traded
Executive Summary
BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY from €182.8M) and a net loss of €531.9M (vs. €415.8M loss a year ago), driven by declining COVID-19 vaccine sales. The company reaffirmed FY2026 revenue guidance of €2.0-2.3B and announced a planned $1.0B share repurchase program, a manufacturing consolidation affecting ~1,860 positions, and multiple oncology pipeline catalysts including six late-stage data readouts expected in 2026. The co-founders will transition to a new independent company by end of 2026, triggering a CEO/CFO succession search.
Key Facts
- Q1 2026 revenue of €118.1M, down 35.4% YoY from €182.8M
- Q1 2026 net loss of €531.9M, widening from €415.8M loss in Q1 2025
- Diluted loss per share of €2.10 (Q1 2025: €1.73)
- Cash, cash equivalents and security investments of €16.8B as of March 31, 2026
- FY2026 revenue guidance reaffirmed at €2.0-2.3B
- Planned share repurchase program of up to $1.0B over twelve months
- Manufacturing consolidation to exit sites in Idar-Oberstein, Marburg, Singapore and CureVac sites, affecting ~1,860 positions
- Expected recurring annual cost savings of ~€500M by 2029 from manufacturing consolidation
- Five additional pivotal trials for pumitamig initiated in Q1 2026 in collaboration with Bristol Myers Squibb
- Six late-stage pipeline data readouts expected in 2026 across immunomodulators, ADC and mRNA programs
- Co-founders Ugur Sahin and Ozlem Tureci to transition to new independent company by end of 2026; Supervisory Board initiated CEO/CFO succession search
- Gotistobart Phase 3 data showed 54% reduction in risk of death vs docetaxel in squamous NSCLC
- Trastuzumab pamirtecan BLA filing planned in 2026 for HER2-expressing endometrial cancer
Financial Impact
Revenue declined 35% YoY to €118.1M; net loss widened 28% to €531.9M; cash position remains strong at €16.8B; $1.0B buyback authorized; ~€500M annual cost savings targeted by 2029
Risk Factors
- Continued COVID-19 vaccine revenue decline faster than guided
- CEO/CFO transition creates strategic uncertainty and potential talent drain
- Oncology pipeline clinical trial failures or delays
- Manufacturing consolidation execution risk and associated exit costs
- Dilution from share repurchase program if not executed efficiently
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000030 |
| Document: a992bntx1q2026presentati.htm | 0001776985-26-000030 |
| Document: form6-kq12026earningsprear.htm | 0001776985-26-000030 |
| Document: 0001776985-26-000030-index-headers.html | 0001776985-26-000030 |
| Document: 0001776985-26-000030-index.html | 0001776985-26-000030 |
| Document: 0001776985-26-000030.txt | 0001776985-26-000030 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers